These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

34 related articles for article (PubMed ID: 25419792)

  • 1. Attentional and clinical neuroleptic response in schizophrenia: a study with the continuous performance test.
    Serper MR; Harvey PD; Davidson M
    Cogn Neuropsychiatry; 1997 Nov; 2(4):241-9. PubMed ID: 25419792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The vigilance paradigm in schizophrenia research - studies on the Continuous Performance Test (CPT)].
    Mass R
    Fortschr Neurol Psychiatr; 2002 Jan; 70(1):34-9. PubMed ID: 11791192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attentional predictors of clinical change during neuroleptic treatment in schizophrenia.
    Serper MR; Davidson M; Harvey PD
    Schizophr Res; 1994 Aug; 13(1):65-71. PubMed ID: 7947417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation trial on the efficacy of neuroleptics on the outcome of schizophrenia].
    Dollfus S; Petit M
    Encephale; 1991; 17(4):247-53. PubMed ID: 1683625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of neuroleptic dosage and extrapyramidal side effects on schizophrenic basic symptoms.
    Moritz S; Krausz M; Gottwalz E; Andresen B
    Compr Psychiatry; 2000; 41(4):284-8. PubMed ID: 10929797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Schizophrenic disorders--does cognitive dysfunction relate to characteristics of course and psychopathology of the illness?].
    Wciórka J; Bembenek A; Hintze B; Kühn-Dymecka A
    Psychiatr Pol; 2006; 40(5):867-84. PubMed ID: 17217232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Influence of attention on an auditory-verbal learning test in schizophrenic patients].
    Huguelet P; Nicastro R; Zanello A
    Encephale; 2002; 28(4):291-7. PubMed ID: 12232538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [ERPs changes during neuroleptic treatment in schizophrenia--a vulnerability marker in schizophrenia].
    Asato N; Hirayasu Y; Hiramatsu K; Ohta H
    Seishin Shinkeigaku Zasshi; 1999; 101(3):254-76. PubMed ID: 10375977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurocognition, psychopathology, and subjective disturbances in schizophrenia: a comparison between short-term and remitted patients.
    Comparelli A; De Carolis A; Corigliano V; Romano S; Kotzalidis G; Brugnoli R; Tamorri S; Curto M; Tatarelli R; Ferracuti S; Girardi P
    Compr Psychiatry; 2012 Oct; 53(7):931-9. PubMed ID: 22444951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia.
    Meltzer HY; Bobo WV; Lee MA; Cola P; Jayathilake K
    Psychiatry Res; 2010 May; 177(3):286-93. PubMed ID: 20378185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Could we use a serum level of glycine as a prognostic factor of its efficacy in schizophrenic patients?].
    Strzelecki D; Rabe-Jabłońska J
    Psychiatr Pol; 2010; 44(3):395-404. PubMed ID: 20672518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Psychopathology and outcome in first-admission schizophrenia: a 13-year follow-up study at a medical school hospital].
    Kobayashi T
    Seishin Shinkeigaku Zasshi; 2001; 103(5):383-410. PubMed ID: 11510079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cause of mortality in schizophrenic patients: prospective study of years of a cohort of 150 chronic schizophrenic patients].
    Bralet MC; Yon V; Loas G; Noisette C
    Encephale; 2000; 26(6):32-41. PubMed ID: 11217537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A significant correlation between ward temperature and the severity of symptoms in schizophrenia inpatients--a longitudinal study.
    Shiloh R; Munitz H; Stryjer R; Weizman A
    Eur Neuropsychopharmacol; 2007; 17(6-7):478-82. PubMed ID: 17234387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Complete neuroleptic withdrawal in patients with schizophrenia with intense symptoms and resistant to treatment].
    Wolf MA; Bailly L; Diener JM; Martinet JP; Peretti S; Garneau Y
    Encephale; 1991; 17(4):255-61. PubMed ID: 1683626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects.
    Kinon BJ; Kane JM; Chakos M; Munne R
    Psychopharmacol Bull; 1993; 29(3):365-9. PubMed ID: 7907184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmaco-epidemiological study on antipsychotic drug prescription in French Psychiatry: Patient characteristics, antipsychotic treatment, and care management for schizophrenia].
    Brunot A; Lachaux B; Sontag H; Casadebaig F; Philippe A; Rouillon F; Cléry-Melin P; Hergueta T; Llorca PM; Moreaudefarges T; Guillon P; Lebrun T
    Encephale; 2002; 28(2):129-38. PubMed ID: 11972139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life in schizophrenia: Impact of psychopathology, patients' gender and antipsychotic treatment.
    Konieczyńska MJ
    Int J Psychiatry Clin Pract; 2001; 5(1):19-26. PubMed ID: 24936992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Frontal dementia or dementia praecox? A case report of a psychotic disorder with a severe decline].
    Vanderzeypen F; Bier JC; Genevrois C; Mendlewicz J; Lotstra F
    Encephale; 2003; 29(2):172-80. PubMed ID: 14567169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.